Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s Spravato Gets EU Okay For Drug-Resistant Depression

Nasal Spray Completes Approval Process Unscathed

Executive Summary

Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.

You may also be interested in...



EU Approval Delay for Janssen’s Spravato?

The EMA has received written interventions from third parties relating to its CHMP opinion that the controversial antidepressant should receive EU approval.

New Phase II Data Bolster vTv Therapeutics’ Glucokinase Activator Aspirations

The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.

Insmed Goes Full Steam Ahead With Bronchiectasis Candidate

Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141385

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel